Hyderabad-based NATCO Pharma Ltd has announced that its co-development and marketing partner, Dr Reddy’s Laboratories Ltd, has filed for registration of doxorubicin hydrochloride liposome injection for intravenous use, in the European markets.

It is the therapeutic equivalent generic version of Janssen’s brand, Doxil, which is predominantly used for the treatment of metastatic breast cancer, advanced ovarian cancer and progressive multiple myeloma.

The Doxil brand, 2mg/ml, had sales of approximately $130.5 million in Europe for the 12 months ending December 31, 2017, according to Quintiles IMS.

comment COMMENT NOW